Abstract:
A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.
Abstract translation:公开了一种新型P-选择素配体糖蛋白,其包含SEQ ID NO:2所示的氨基酸序列或SEQ ID NO:4所示的氨基酸序列。 还公开了编码P-选择素配体蛋白的DNA序列,以及载体,宿主细胞和制备P-选择蛋白配体蛋白的方法。 还公开了含有P-选择素配体蛋白质的药物组合物和治疗由P-选择蛋白和E-选择素介导的细胞间粘附特征的炎性疾病状态的方法。
Abstract:
Disclosed are system 100 and method of energy efficient hot and cold water management. The system 100 comprises: a control unit 101 for dynamically controlling the functioning of the system 100; at least a water storage tank 102 with at least one of a water level sensor, at least a heating element 1021, at least a temperature sensor 1022 or any combination thereof; at least an auxiliary water storage tank 103 with at least one of a water level sensor, at least a temperature sensor 1032; at least a water mixer unit 105 having at least a temperature sensor 1051; a user interface unit 1012 for controlling and monitoring different parameters including temperature, water level, opening and closing of valves 108 and 109; and a power supply with power backup unit 104 for providing basic power for proper functioning of the system 100.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
Abstract:
A system in which firmware residing in ROM may be upgraded without re-spinning silicon. A one-bit flag may be assigned for each patchable function representing a firmware upgrade. The first statement of each function may check its associated flag and determine if patch-code should be executed in place of the current function residing in ROM. If the flag is not set, the code may continue executing normally. If the flag is set, a function identifier may be placed into a global memory location, and an assembly language “jump” instruction may be executed, redirecting program control to a specified location in a volatile Scratch Read Only Memory (SROM) where the corresponding patched code may be stored. If more than one function is patched, the global identifier may be used to determine which patched function to execute. Using an assembly language “jump” instruction to redirect control results in the patched function's returning normally to its calling function once it has completed executing.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.